Shanghai Creek Pharmaceutical

Shanghai Creek Pharmaceutical Technology (also known as CorreGe) is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene therapies for ophthalmic diseases. The company utilizes its proprietary cceAAV (covalently closed-end double-stranded adeno-associated virus) platform to create vectors with improved packaging efficiency, higher transgene expression, and enhanced safety profiles. Its lead candidate, CRG-B191, is an AAV-based gene therapy expressing an anti-VEGF protein (aflibercept-Fc-YTE) for the treatment of wet age-related macular degeneration (nAMD). CorreGe aims to provide a one-time, long-lasting treatment solution to reduce the burden of frequent intravitreal injections for patients with retinal vascular diseases. The company is currently advancing its pipeline through clinical trials in China and has received backing from investors such as Dao Tong Investment.